Cost-effectiveness of the COPD Patient Management European Trial home-based disease management program
Received 4 May 2018
Accepted for publication 19 December 2018
Published 14 March 2019 Volume 2019:14 Pages 645—657
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Justinn Cochran
Peer reviewer comments 2
Editor who approved publication: Dr Richard Russell
Jean Bourbeau,1 Denis Granados,2 Stéphane Roze,3 Isabelle Durand-Zaleski,4 Pere Casan,5 Dieter Köhler,6 Silvia Tognella,7 Jose Luis Viejo,8 Roberto W Dal Negro,9 Romain Kessler10
1Department of Medicine, Division of Experimental Medicine, Respiratory Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Centre, Montreal, QC, Canada; 2Medical R&D – Real World & Clinical Evidence, Air Liquide Santé International, Gentilly, France; 3Department of Health Economics, HEVA HEOR, Lyon, France; 4URCEco Ile de France Hôpital de l’Hotel Dieu, Paris, France; 5Department of Pneumology, Asturias University Hospital, Oviedo, Spain; 6Department of Internal Medicine, Kloster Grafschaft Specialised Hospital, Schmallenberg, Germany; 7Department of Pneumology, Bussolengo General Hospital, Bussolengo, Italy; 8Department of Pneumology, Burgos University Hospital, Burgos, Spain; 9Department of Pneumology, Bussolengo Hospital, Bussolengo, Italy; 10Department of Pneumology, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France
Purpose: Efficient management of COPD represents an international challenge. Effective management strategies within the means of limited health care budgets are urgently required. This analysis aimed to evaluate the cost-effectiveness of a home-based disease management (DM) intervention vs usual management (UM) in patients from the COPD Patient Management European Trial (COMET).
Methods: Cost-effectiveness was evaluated in 319 intention-to-treat patients over 12 months in COMET. The analysis captured unplanned all-cause hospitalization days, mortality, and quality-adjusted life expectancy. Costs were evaluated from a National Health Service perspective for France, Germany, and Spain, and in a pooled analysis, and were expressed in 2015 Euros (EUR). Quality of life was assessed using the 15D health-related quality-of-life instrument and mapped to utility scores.
Results: Home-based DM was associated with improved mortality and quality-adjusted life expectancy. DM and UM were associated with equivalent direct costs (DM reduced costs by EUR -37 per patient per year) in the pooled analysis. DM was associated with lower costs in France (EUR -806 per patient per year) and Spain (EUR -51 per patient per year), but higher costs in Germany (EUR 391 per patient per year). Evaluation of cost per death avoided and cost per quality-adjusted life year (QALY) gained showed that DM was dominant (more QALYs and cost saving) in France and Spain, and cost-effective in Germany vs UM. Nonparametric bootstrapping analysis, assuming a willingness-to-pay threshold of EUR 20,000 per QALY gained, indicated that the probability of home-based DM being cost-effective vs UM was 87.7% in France, 81.5% in Spain, and 75.9% in Germany.
Conclusion: Home-based DM improved clinical outcomes at equivalent cost vs UM in France and Spain, and in the pooled analysis. DM was cost-effective in Germany with an incremental cost-effectiveness ratio of EUR 2,541 per QALY gained. The COMET home-based DM intervention could represent an attractive alternative to UM for European health care payers.
Keywords: cost-effectiveness, France, Spain, Germany, home-based disease management, COPD
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]